Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea

Journal of Cosmetic Dermatology

Volumn 11, Issue 1, 2012, Pages 37-41

  Berardesca, Enzo ^a   Iorizzo, Matilde ^b   Abril, Elva ^a   Guglielmini, Giancarlo ^c   Caserini, Maurizio ^d   Palmieri, Renata ^d   Piérard, Gérald E ^e  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b Sinerga SpA ^*

^c Scientific Department   (Italy)

^d Polichem SA   (Switzerland)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Azeloglicina ; Erythema; Potassium azeloyl diglycinate (PAD); Rosacea; Skin hydration

Indexed keywords

AZELOGLICINA; CHITOSAN; HYDROXYPROPYLCHITOSAN; P 3075; PLACEBO; POTASSIUM AZELOYL DIGLYCINATE; POTASSIUM DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLUSHING; HUMAN; HYDRATION; LABORATORY DEVICE; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SKIN BURNING SENSATION; SKIN PROTECTION; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; CHI-SQUARE DISTRIBUTION; CHITOSAN; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; ROSACEA; SKIN; YOUNG ADULT;

EID: 84857482678     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2011.00598.x     Document Type: Article

References (15)

1. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006; 78: 97-100.
2. Culp B, Scheinfeld N. Rosacea: a Review. Pharm Ther 2009; 34: 38-45.
3. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41.
4. Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res 2005; 10: 454-6.
5. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.
6. 2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1996; 271: 21793-7.
7. Piérard-Franchimont C, Quatresooz P, Piérard GE. Incidental control of rosacea by somatostatin. Dermatology 2003; 206: 249-51.
8. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
9. Maramaldi G, Esposito M. Potassium Azeloyl Diglycinate. Cosm & Toil 2002; 117: 3.
10. Sparavigna A, Setaro M, Frisenda L. Physical and microbiological properties of a new nail protective medical device. J Plastic Dermatol 2008; 4: 1.
11. Monti D, Saccomani L, Chetoni P et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005; 31: 11-17.
12. Berardesca E, Borroni G. Instrumental evaluation of cutaneous hydration. Clin Dermatol 1995; 13: 323-7.
13. Piérard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998; 10: 1-11.
14. Berardesca E, Cameli N, Cavallotti C et al. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol 2008; 7: 8-14.
15. Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4: S19-22.